Pharma major Lupin announced the exclusive launch of its Ranolazine Extended-Release (ER) Tablets, 500mg and 1000mg.
 
Lupin's Ranolazine ER Tablets, 500mg and 1000mg are a generic version of Gilead Sciences, Inc.'s Ranexa ER Tablets, 500mg and lOOOmg. Ranolazine is indicated for the treatment of chronic angina.

Ranolazine ER Tablets, 500mg and 1000mg had an annual sales of approximately USD 945 million in the US (IQVIA MAT December 2018).

Nilesh Gupta, Managing Director, Lupin, said, "We are excited about the launch of generic Ranolazine as an exclusive generic in the US. This is a meaningful product and further strengthens our portfolio of generic products in the US. Launching exclusive and semi-exclusive generics is an important stepping stone as we transition to more complex generics. Products like Ranolazine bring significant savings to US consumers and are a key part of our vision to bring exclusive high quality, affordable medicines to market.''

Shares of the company declined Rs 4.7, or 0.61%, to trade at Rs 763.00. The total volume of shares traded was 51,275 at the BSE (2.50 p.m., Thursday).